ArticleAlpha psychiatry2026
Network Pharmacology Reveals the Potential Mechanism of Ketamine in Improving Cognitive Impairment in Patients With Depression.
Article in Alpha psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ketamine may have antidepressant and anti-suicidal effects. However, the mechanism underlying ketamine-mediated improvement in cognitive impairment in patients with depression remains unclear. To improve patient cognition in depression using molecular docking and network pharmacology, we examined ketamine's key targets and identified its molecular mechanisms. Methods: To gain target information about cognitive impairment (1983) and depression (1874), we used three databases, including Online Mendelian Inheritance in Man, GeneCards, and DisGENET. Information on ketamine targets (63) was retrieved from public databases. To locate signaling pathways and core targets, we conducted bioinformatics analysis, including an enrichment analysis and protein-protein interaction (PPI) network analysis. To assess the interaction between core targets and ketamine, we carried out molecular docking. Results: We identified 20 ketamine target proteins of ketamine related to depression and cognitive impairment. Enrichment analyses revealed that ketamine influenced depression and cognitive function through multiple pathways, targets, and overall synergy. The important signaling pathways identified were "amphetamine addiction" and "dopaminergic synapse". Five core genes (monoamine oxidase (MAO)-A, Conclusions: The antidepressant and cognitive-enhancing effects of ketamine are primarily mediated through targets associated with inflammation, neural signaling, tumors, and neurodegeneration, as well as pathways such as amphetamine addiction, dopaminergic synapse, and the cyclic adenosine monophosphate (cAMP) signaling pathway. The findings provide theoretical support and guidance for optimizing clinical application strategies of ketamine and for designing new drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.